Upstream Bio (NASDAQ:UPB) Coverage Initiated by Analysts at William Blair

William Blair started coverage on shares of Upstream Bio (NASDAQ:UPB) in a research note released on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating on the stock.

Separately, TD Cowen initiated coverage on shares of Upstream Bio in a report on Tuesday. They set a “buy” rating for the company.

Upstream Bio Price Performance

Shares of NASDAQ UPB opened at $27.39 on Tuesday. Upstream Bio has a 12 month low of $20.74 and a 12 month high of $28.98.

Insider Activity at Upstream Bio

In related news, major shareholder Ai Upstream Llc bought 1,175,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the acquisition, the insider now owns 1,175,000 shares in the company, valued at $19,975,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, major shareholder Ai Upstream Llc bought 1,175,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the acquisition, the insider now owns 1,175,000 shares in the company, valued at $19,975,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Erez Chimovits acquired 825,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the purchase, the director now owns 4,554,873 shares of the company’s stock, valued at $77,432,841. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.